Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early treatment.

G Comi1

  • 1Department of Neurology and Neurorehabilitation, Università Vita-Salute, Istituto Scientifico San Raffaele, Via Olgettina 60, I-20132 Milan, Italy. comi.giancarlo@hsr.it

Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|May 19, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial.

Journal of neurology, neurosurgery, and psychiatry·2011
Same author

Voxelwise assessment of the regional distribution of damage in the brains of patients with multiple sclerosis and fatigue.

AJNR. American journal of neuroradiology·2011
Same author

Thalamic damage predicts the evolution of primary-progressive multiple sclerosis at 5 years.

AJNR. American journal of neuroradiology·2011
Same author

Cortical lesions in children with multiple sclerosis.

Neurology·2011
Same author

Sensorimotor functional connectivity changes in amyotrophic lateral sclerosis.

Cerebral cortex (New York, N.Y. : 1991)·2011
Same author

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

European journal of neurology·2011
Same journal

Asymmetrical muscular disorder with normal creatine kinase (CK) and electromyography (EMG): the challenging diagnosis of muscular polyarteritis nodosa (MPAN), case report and literature review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Neuropsychological assessment in adult epilepsy: rationale, test selection, and clinical integration across non-surgical care in Italian patients.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Early implementation of transradial mechanical thrombectomy in a primary stroke center: a sequential cohort propensity score-matched study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Atypical phenotype of CADASIL in the c.451 C > G (Q151E) mutation of the NOTCH3 gene.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Characterization of sensory nerve conduction abnormalities at the time of ALS diagnosis.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same journal

Positron emission tomography for diagnosing cerebrovascular disorders: a scoping review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
See all related articles

Early treatment for multiple sclerosis (MS) with immunomodulatory therapies like interferon-beta reduces disease activity and disability. Prompt intervention is key, as early inflammation causes irreversible axonal damage, impacting long-term prognosis.

Area of Science:

  • Neurology
  • Immunology
  • Clinical Trials

Background:

  • Relapsing-remitting multiple sclerosis (MS) and secondary progressive MS (SPMS) are characterized by inflammatory activity.
  • Immunomodulatory treatments like interferon-beta and glatiramer acetate are used in MS management.
  • Early inflammatory processes in MS can lead to irreversible axonal damage and long-term disability.

Purpose of the Study:

  • To evaluate the efficacy of early immunomodulatory treatment in multiple sclerosis.
  • To assess the impact of treatment on disease activity, disability accumulation, and inflammatory markers.
  • To determine if early treatment initiation influences long-term outcomes in MS patients.

Main Methods:

  • Analysis of Class I clinical trials, including double-blind, placebo-controlled studies (e.g., Early Treatment of Multiple Sclerosis, BENEFIT).

Related Experiment Videos

  • Assessment of clinical outcomes such as disease activity and disability progression.
  • Utilization of magnetic resonance imaging (MRI) to measure inflammatory activity.
  • Review of pathological studies investigating early axonal damage in MS.

    • Main Results:

    • Immunomodulatory treatments (interferon-beta, glatiramer acetate) significantly reduced disease activity and disability accumulation in relapsing-remitting MS.
    • Interferon-beta-1b showed positive effects in secondary progressive MS.
    • While clinical effects were modest, MRI revealed marked reductions in inflammatory activity.
    • Early inflammatory activity is linked to irreversible axonal damage and predicts long-term disability.

    Conclusions:

    • Early treatment initiation with immunomodulatory therapies offers significant benefits for patients with multiple sclerosis.
    • Prompt intervention can mitigate irreversible axonal damage and potentially improve long-term disability outcomes.
    • Clinical trial evidence supports the recommendation for early treatment in MS management.